Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)-Reference-Cited by-同舟云学术

Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)

Published:2020-07-28 Issue:8 Volume:37 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Marvaso Giulia^ORCID,Gugliandolo Simone Giovanni,Bellerba Federica,Gandini Sara,Corrao Giulia,Volpe Stefania,Rojas Damaris Patricia,Riva Giulia,Zerini Dario,Pepa Matteo,Fodor Cristiana Iuliana,La Rocca Eliana,Pricolo Paola,Alessi Sarah,Petralia Giuseppe,Mistretta Francesco Alessandro,Cambria Raffaella,Cattani Federica,De Cobelli Ottavio,Orecchia Roberto,Jereczek-Fossa Barbara Alicja

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-020-01397-3.pdf

Reference46 articles.

1. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–24. https://doi.org/10.1056/NEJMoa1606220.

2. Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014;15:1109–18. https://doi.org/10.1016/S1470-2045(14)70361-4.

3. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17–24. https://doi.org/10.1016/j.ijrobp.2010.10.075.

4. Catton CN, Lukka H, Gu C-S, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:1884–900. https://doi.org/10.1200/JCO.2016.71.7397.

5. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–60. https://doi.org/10.1016/S1470-2045(16)30102-4.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-06

2. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial;Radiation Oncology;2024-05-03

3. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial “GIVE ME FIVE”;World Journal of Urology;2024-03-16

4. Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials;Cancers;2023-10-08

5. Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors;Acta Oncologica;2023-10-06